Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

Imaging Studies for Cardiovascular System V: CT

Imaging Studies for Cardiovascular System V: CT

Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...

Cardiac Catheterization IV: Nursing Management

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study.

Breast (Edinburgh, Scotland)·2025

Same author

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

ESMO open·2024

Same author

Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.

ESMO open·2023

Same author

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Oncogene·2023

Same author

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Oncogene·2023

Same author

[Congenital thoracic deformities and 3D custom-made implants. New classification based on a series of 789 treated cases].

Annales de chirurgie plastique et esthetique·2022

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

[Bevacizumab and invasive procedures: practical recommendations].

V Gounant¹, B Milleron, J Assouad

¹Service de Pneumologie et réanimation respiratoire, Hôpital Tenon, AP-HP, Université Paris VI, Paris, France. valerie.gounant@tnn.aphp.fr

Revue Des Maladies Respiratoires

|March 26, 2009

Summary

This summary is machine-generated.

Bevacizumab improves survival in non-small cell lung cancer but increases bleeding risks. Recommendations are provided for managing invasive procedures during treatment.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Area of Science:

Oncology
Vascular Biology

Context:

Bevacizumab, an anti-angiogenic drug, is a first-line chemotherapy for metastatic non-small cell lung cancer.
Its mechanism involves inhibiting vascular endothelial growth factor (VEGF), crucial for scar formation and hemostasis.
This anti-angiogenic action can lead to increased bleeding risks, particularly with invasive procedures.

Purpose:

To analyze the specific risks of bleeding associated with invasive procedures in patients treated with Bevacizumab.
To provide practical recommendations for managing these risks in clinical practice.

Summary:

Bevacizumab combined with platinum-based chemotherapy improves survival in metastatic non-small cell, non-squamous bronchial carcinoma.
The drug's anti-angiogenic properties inhibit scar formation, potentially increasing bleeding complications.
Recommendations include specific delays between device implantation, Bevacizumab initiation, and surgical procedures.

Impact:

Provides evidence-based guidelines for safe management of patients undergoing invasive procedures while on Bevacizumab therapy.
Aims to minimize bleeding complications and optimize patient outcomes in non-small cell lung cancer treatment.
Highlights the importance of multidisciplinary team approach for managing patients receiving Bevacizumab.